PET for Dementia Trials
Additionally, in a National Coverage Determination for PET (FDG) for Dementia and Neurodegenerative Diseases (220.6.13) the Centers for Medicare & Medicaid Services (CMS) indicated that an FDG-PET scan is considered reasonable and necessary in patients with mild cognitive impairment or early dementia only in the context of an approved clinical trial that contains patient safeguards and protections to ensure proper administration, use and evaluation of the FDG-PET scan.
Facility Name | Provider Number | Date Approved | State |
---|---|---|---|
95 1644600
|
2009-10-09
|
California
|
|
460009
|
2009-02-17
|
Utah
|
|
1073605879
|
2009-02-17
|
South Carolina
|
|
W11817A
|
2007-01-12
|
California
|
|
HW13029
|
2006-06-07
|
California
|
|
14414A
|
2007-03-12
|
New York
|